Trial intelligence / Profile preview

Physostigmine salicylate for treatment of postoperative delirium after coronary bypass surgery

2008-006221-14Phase 3Terminated

Sponsor: Company: Dr. Franz KÃ¶hler Chemie GmbH
Start: Aug 2009
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, single-arm trial of physostigmine in delirium, sponsored by Company: Dr. Franz KÃ¶hler Chemie GmbH. Primary endpoint: CAM-ICU response at 30 minutes. Started Aug 2009; status: terminated.

Drugs

physostigmine

Conditions

delirium

Beyond the preview

Go deeper on 2008-006221-14.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-006221-14.